Dong-A ST concludes co-sale agreement of antihypertensive ‘Edarbi’ with Takeda
Dong-A ST announced on the 30th that conclusion of a joint sale and marketing agreement of ‘Edarbi,’ an ARB(angiotensin II receptor blocker) antihypertensive, with Takeda Pharmaceuticals Korea.
Under the agreement, Dong-A ST and Takeda Pharmaceuticals Korea will jointly carry out a business for ...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.